Muhıt Özcan

机构：Ankara University · ORCID：0000-0002-1326-1918

发表论文 400 篇 · 总被引 5729 次 · h-index 31

代表论文

• Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial (2025 · Journal of Clinical Oncology · 被引 22)
• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 20)
• Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2025 · Journal of Clinical Oncology · 被引 18)
• Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study (2025 · Blood · 被引 6)
• Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor (2025 · Blood · 被引 2)
• Acute myeloid leukemia: a brief historical perspective of AML treatment (2025 · Hematology · 被引 2)